Key Takeaways MLTX surged 18% on a report that Merck submitted a non-binding buyout offer earlier this year. The rumored deal would value MoonLake at over $3 billion, though the initial offer was reportedly rejected. Merck's interest may reflect a strategy to diversify beyond Keytruda by adding novel drug candidatesShares of small-biotech MoonLake Immunotherapeutics (MLTX) rose 18% yesterday following a report issued by the Financial Times (FT), which stated that pharma giant Merck (MRK) is interested in ...

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

《金融时报》在美东时间周一报道称，制药巨头默沙东(MRK.US)今年早些时候曾向生物科技公司 MoonLake Immunotherapeutics(MLTX.US)提出收购要约。消息发布后，MoonLake股价在美股盘后交易 中大幅飙升，一度暴涨超30%，截至发稿，该股上涨约20%。 报道称，默沙东提出了一份金额超30亿美元的非约束性报价，但初步报价遭到拒绝。三位知情人士透 露，两家公司之间的谈判仍有可能重启。 值得注意的是，默沙东多年来依赖畅销药Keytruda(可瑞达)驱动增长，但其专利将于2028年开始到期。 此外，该公司在中国市场的Gardasil(佳达修)疫苗收入近期持续下滑。 今年4月，默沙东称拟斥资10亿美元在美国建厂，以确保Keytruda供应免受关税冲击。随着针对行业的 关税迫在眉睫，默沙东成为最新一家增加美国国内投资的制药公司。该工厂将生产一种新型的、用户友 好的该公司重磅癌症治疗药物Keytruda的配方;该工厂还将成为该公司在美国的第一个Keytruda内部生产 基地，确保美国患者获得国内生产的药物。 截至发稿，默沙东美股盘后微跌0.07%。 《金融时报》分析称，默沙东在MoonLa ...

默克制药洽谈收购生物科技公司Moonlake ImmunoTherapeutics。（英国金融时报） ...

MoonLake Immunotherapeutics (MLTX) closed the last trading session at $36.99, gaining 0.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $76.43 indicates a 106.6% upside potential.The mean estimate comprises 14 short-term price targets with a standard deviation of $13.12. While the lowest estimate of $55 indicates a 48.7% increase from the current price level, the most optimistic ...

Commission file number: 001-39630 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to MOONLAKE IMMUNOTHERAPEUTICS (Exact Name of Registrant as Specified in Its Charter) Cayman Islands 98-1711963 (State or other ...

MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update Continued to make significant progress with the development of the Nanobody® sonelokimab across portfolio of indications, including Phase 3 studies in hidradenitis suppurativa (HS), psoriatic Arthritis (PsA) and adolescent HS, as well as Phase 2 studies in palmoplantar pustulosis (PPP) and axial spondyloarthritis (axSpA)Announced completion of enrollment of patients in the Phase 3 program in HS (the VELA ...

MoonLake Immunotherapeutics Capital Markets Update New York April 29th 2025 © 2025 | Proprietary | MoonLake TX W: moonlaketx.com | E: info@moonlaketx.com Welcome to our Capital Markets Update Date: April 29th, 2025 Time: 8.30 am EST Location: New York | Topic | Sub-topics | | Speaker | Timing | | --- | --- | --- | --- | --- | | Introduction | - | Welcome | Jorge | 10 mins | | | - | MLTX & SLK summary | | | | | - | Key points for the session | | | | HS: Clinical & | - | VELA recruitment & baseline | Kristian ...

MoonLake Immunotherapeutics (MLTX) 2025 Capital Markets Day April 29, 2025 02:15 PM ET Speaker0 Good morning. Good afternoon. Welcome to the capital markets update of Moon Lake Immunotherapeutics. My name is Matthias Bodenstadt. I'm the chief financial officer of the company. With me here today are CEO and co founder, Georges Santos Dasilva and our CSO and co founder, Professor Christian Reich. It's a pleasure to have you here today for the capital markets update. We have a very exciting agenda. We will pro ...

MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29 Zug, Switzerland, April 25, 2025 – MoonLake Immunotherapeutics (Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, will host a virtual Capital Markets Day for investors and analysts on Tuesday, April 29, 2025. The event will highlight recent financial and clinical milestones and provide future strategic updates. The webcast, streamed live from New York, will s ...